Hepatitis B News and Research

Latest Hepatitis B News and Research

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

Travelers may risk both health and travel insurance coverage by not getting vaccinated

With tens of thousands of people set to travel abroad over the Christmas period, AA Travel Insurance are today urging travellers to be properly vaccinated before travelling.

8 Dec 2009

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection provides the following recap of yesterday's investor conference call, which discussed the Company’s acquisition of intellectual property rights from Los Alamos National Security.

5 Dec 2009

Sudbury & District Public Health Unit nurses reach tentative settlement with employer

Following a long and difficult negotiations process, public health nurses with the Sudbury & District Public Health Unit have reached a tentative settlement with their employer.

4 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Opinions: Media coverage of HIV/AIDS; WTO and global health; G8, HIV/AIDS; stopping syringe reuse

In a New Republic/NPR opinion piece, Harold Pollack, an associate professor at the University of Chicago School of Social Service Administration, looks at the media's coverage of World AIDS Day. "Almost six thousand people died of AIDS [Tuesday]. ... That it happened to be World AIDS Day was almost incidental. AIDS was certainly incidental to much of the mainstream media.

4 Dec 2009

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

3 Dec 2009

Tripep receives approval to extend ChronVac-C study

Today Tripep (STO:TPEP) received the approval from the Swedish Medical Products Agency and the local ethical committee to give three patients in the highest dose group in the ChronVac-C® study one additional treatment with the therapeutic vaccine.

3 Dec 2009

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections.

3 Dec 2009

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

The University of Pittsburgh's McGowan Institute for Regenerative Medicine, which connects scientists who work on tissue engineering, cell therapies, artificial organs and biodevices, has been awarded a Shared University Research (SUR) Award from IBM ( IBM). The IBM SUR Award will provide IBM computer hardware, software and services to Pitt for its cutting-edge "in silico" biological research, which uses computer simulations to explore biological pathways and test therapeutic interventions.

2 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Study of Acetadote Injection as a cost-saving treatment for acetaminophen poisoning published

Cumberland Pharmaceuticals Inc. announced today that an independently conducted study of Acetadote (acetylcysteine) Injection, or intravenous N-acetylcysteine, as a cost-saving treatment for acetaminophen poisoning was published in Volume 12, Number 4 of the peer-reviewed Journal of Medical Economics, distributed in December.

2 Dec 2009

Russian hepatitis C virus drug market to reach $327M by 2013: Decision Resources

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the hepatitis C virus drug market in Russia will grow nine percent annually over the 2008 - 2013 study period, reaching $327 million by 2013.

1 Dec 2009

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City.

1 Dec 2009

Hepatitis B News and Research

Latest Hepatitis B News and Research

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Travelers may risk both health and travel insurance coverage by not getting vaccinated

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Sudbury & District Public Health Unit nurses reach tentative settlement with employer

New Center for Digestive Care to care for all aspects of digestive disease

New SPC3649 drug found effective in treating HCV infections

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Opinions: Media coverage of HIV/AIDS; WTO and global health; G8, HIV/AIDS; stopping syringe reuse

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Tripep receives approval to extend ChronVac-C study

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Study of Acetadote Injection as a cost-saving treatment for acetaminophen poisoning published

Russian hepatitis C virus drug market to reach $327M by 2013: Decision Resources

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in